News and Trends 8 Jul 2020
Osivax Raises €32M to Develop Universal Coronavirus and Influenza Vaccines
Osivax, a Lyon-based biotechnology company, secured €17.5M from the European Innovation Council and €15.1M from Bpifrance. The funding will be used to develop vaccines that protect from all current – and even future – flu and coronavirus outbreaks. Most current vaccines have a specific target protein they work against. They train the immune system to […]